Mapping out the competitive landscape for the next generation pharma market

As most pharmaceutical, biotechnology and generics companies have now closed the financial books on 2006, Global Insight has take the opportunity to map out the competitive landscape for 2007-10. With traditional big-hitters - such as Pfizer and Amgen in the USA, AstraZeneca in Europe and Takeda in Japan - faltering at the pipeline stage, which movers and shakers are best positioned to assume the mantle of growth in the global pharmaceutical industry? Perhaps more importantly, how are they doing so? What will be the key catalysts?

- The global pharmaceutical industry is still a growth sector, but only just, says the independent analysis and forecasting company. The 2007-10 period should see continued mid-single-digit annual